Inogen (NASDAQ:INGN - Get Free Report) posted its earnings results on Tuesday. The medical technology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.15, Zacks reports. The company had revenue of $80.08 million for the quarter, compared to analysts' expectations of $73.90 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. Inogen updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Inogen Trading Up 4.8 %
NASDAQ:INGN traded up $0.38 during midday trading on Friday, hitting $8.33. 408,849 shares of the stock were exchanged, compared to its average volume of 309,250. Inogen has a one year low of $6.14 and a one year high of $13.33. The business has a 50-day moving average price of $10.18 and a two-hundred day moving average price of $10.21. The company has a market capitalization of $198.40 million, a price-to-earnings ratio of -3.70 and a beta of 1.02.
Analyst Ratings Changes
Several brokerages recently weighed in on INGN. StockNews.com downgraded shares of Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a report on Wednesday.
Read Our Latest Research Report on INGN
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
